Pharmaceutical company to build its Chinese headquarters in WND

Signing ceremony between Dizal Pharmaceutical and Wuxi National Hi-tech District is held on Aug 17. [Photo/wnd.gov.cn]

Dizal Pharmaceutical signed a deal with Wuxi National Hi-tech District to build its Chinese headquarters there on Aug 17.

According to the deal, the Chinese headquarters to be built in WND will establish research and development (R&D), operation, production, sales and distribution centers in stages, to promote innovation in Wuxi's biomedical industry.

Dizal Pharmaceutical is an equally owned, standalone company established by AstraZeneca and the Chinese Future Industry Investment Fund in 2017, with the aim to discover, develop and commercialize potential new medicines to help meet unmet needs globally and to bring innovative new medicines to patients in China faster.

A plan map of Dizal Pharmaceutical's Chinese headquarters in WND [Photo/wnd.gov.cn]

The company incorporates all scientific and technical capabilities of AstraZeneca's Innovation Center China (ICC), and holds exclusive rights to develop and commercialize three potential medicines currently in pre-clinical development from AstraZeneca's pipeline in its main therapy areas of oncology, cardiovascular and metabolic diseases, and respiratory. It also initiates novel clinical programs.

Zhang Xiaolin, CEO of Dizal Pharmaceutical, said with the to-be-built Chinese headquarters, the company will attract more related projects and capital to build WND into a competitive district in the biopharmaceutical industry.